Welcome to our dedicated page for AI / ML Innovations news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML Innovations stock.
AI / ML Innovations Inc. (AIMLF) generates news centered on its use of artificial intelligence and neural networks in digital health, with a strong focus on ECG and cardiac signal interpretation. Many updates relate to activities of its wholly owned subsidiary, NeuralCloud Solutions Inc., which develops platforms such as MaxYield™, CardioYield™, and Insight360™ for clinical, wellness, performance, and veterinary applications.
News items frequently cover commercial term sheets and pilot projects that illustrate how the company’s technology is being evaluated or integrated into real-world environments. Examples include a Commercial Agreement Term Sheet with Lakeshore Cardiology to deploy CardioYield™ for Holter and ambulatory cardiac monitoring workflows, a pilot at The Hospital for Sick Children (SickKids) to assess MaxYield™ in pediatric cardiac care, and a pilot with Cornerstone Physiotherapy to use MaxYield™ and Insight360™ in an emerging elite athlete performance program.
Additional announcements describe non-binding commercial agreements to integrate MaxYield™ and Insight360™ into Culminate H Labs’ INTRINSICA DNA-guided biofeedback wellness ecosystem, and to deploy MaxYield™ and CardioYield™ across Equimetrics’ equine clinical and performance monitoring platforms. Corporate news also includes leadership changes, such as the appointment of a Chief Operating Officer, and the engagement of external communications and investor outreach firms.
Investors and observers who follow AIML-related news can track how the company’s AI-driven ECG platforms are progressing through pilots, term sheets, and early-stage deployments across cardiology, pediatric research, wellness, sports performance, and veterinary health. The news flow offers insight into the company’s commercialization efforts, intellectual property milestones, and evolving partnerships in digital health.
AI/ML Innovations (OTCQB:AIMLF, CSE:AIML) completed a share-for-debt issuance on April 24, 2026, issuing 17,118,420 common shares at a deemed price of Cdn$0.05 per share for total consideration of Cdn$855,921 to settle past services and outstanding indebtedness. Insiders acquired 11,848,000 Subject Shares, triggering a related party designation under MI 61-101, though the company relied on exemptions to avoid formal valuation and minority approval. The Subject Shares carry a statutory hold expiring August 25, 2026. The securities are not registered for sale in the United States.
AI/ML Innovations (OTCQB:AIMLF) completed a previously announced share-for-debt issuance on April 17, 2026, issuing 17,118,420 common shares at a deemed price of C$0.05 per share to settle past services and outstanding indebtedness.
Insiders acquired 11,848,000 of the Subject Shares, triggering a related‑party designation under MI 61-101; the company relied on specified exemptions and the Subject Shares carry a statutory hold until August 18, 2026.
AI/ML Innovations (OTCQB:AIMLF) said its subsidiary Neural Cloud signed a reseller agreement on March 25, 2026 with a European digital cardiac monitoring platform to integrate and resell MaxYield™ ECG signal‑processing technology.
The collaboration aims to expand device‑agnostic, cloud‑based remote ECG and HRV analytics for clinicians, enabling cleaner waveform data for downstream diagnostics and preventive cardiology applications.
AI/ML Innovations (OTCQB:AIMLF) closed the first tranche of a non-brokered private placement to issue $950,000 of convertible debentures on March 27, 2026.
Debentures convert to Units at $0.05 per Unit; each Unit includes one common share and one warrant exercisable at $0.15 for 36 months. Debentures bear 10% annual interest, mature March 27, 2029, and securities are subject to a statutory hold until July 28, 2026. Use of proceeds: general working capital. Offering subject to CSE final approval.
NeuralCloud (AIMLF) entered a research services agreement dated March 18, 2026 with the Baker Heart and Diabetes Institute to apply its MaxYield™ ECG processing platform to existing ECG recordings for a study of heart rate variability in post-exertional malaise.
The service converts PDF ECG traces to EDF, isolates waveform components, and generates beat-level data for HRV analysis; results are expected to support publication within the coming year. Services are non-diagnostic.
AI/ML Innovations (CSE:AIML | OTCQB:AIMLF) announced a proposed non-brokered private placement of convertible debentures of up to $3,000,000. Debentures convert into Units at $0.05 per Unit (one share + one warrant), bear 10% annual interest, and mature in 3 years.
Each Warrant is exercisable at $0.15 for 36 months from issuance. Accrued unpaid interest may convert into Units on the same terms. The Offering is subject to closing conditions and Canadian Securities Exchange approval; securities will not be offered in the United States.
AIML (OTCQB:AIMLF) said its subsidiary Neural Cloud entered a distribution agreement with Chile-based Intelimed on Feb 18, 2026 to commercialize MaxYield™, CardioYield™, and Insight360™ across Latin America. Intelimed is exclusive in Chile and non-exclusive elsewhere, targeting hospitals, clinics, OEMs, telemedicine providers and research institutions.
The partnership aims to expand access to AI-driven cardiac software, leveraging Intelimed's regional engagements and platform that aggregates FDA- and CE-authorized diagnostic tools.
AI/ML Innovations (OTCQB:AIMLF) subsidiary NeuralCloud signed a non-binding agreement with Movesense on February 11, 2026 to pilot AI-powered 1-lead ECG and Holter reporting in a third-party health system and affiliated clinics. The pilot will deploy NeuralCloud's MaxYield™ and CardioYield™ platforms alongside Movesense wearable hardware for operational validation and potential commercial rollout.
The collaboration focuses on increasing ECG screening reach, standardizing reporting, and scaling ambulatory monitoring capacity without materially increasing clinical workload; future commercialization depends on pilot results, definitive agreements, and regulatory considerations.
Neural Cloud, a wholly owned subsidiary of AI/ML Innovations (OTCQB:AIMLF), retained U.S. sales recruiter Commission Wolf on February 9, 2026 to build a U.S. commercial sales infrastructure for MaxYield™ and CardioYield™.
The agreement targets recruitment of 1099 independent sales representatives with cardiology relationships to support market entry as regulatory milestones are met and to accelerate pilot-to-commercial conversions.
AI/ML Innovations (OTCQB:AIMLF) appointed Dr. Paul Dorian as Medical Innovation Architect and Head of the Medical Advisory Board, effective January 28, 2026. The move follows his months-long collaboration on AIML's MaxYield™, CardioYield™, and Insight360™ platforms and aims to support clinical validation, regulatory engagement, and global deployment.
This leadership transition succeeds Peter Kendall and reinforces the company’s focus on arrhythmia care, ambulatory monitoring, and AI-driven ECG diagnostics as AIML advances clinical studies and market-readiness.